Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CNTX-6016 by Centrexion Therapeutics for Diabetic Neuropathic Pain: Likelihood of Approval
CNTX-6016 is under clinical development by Centrexion Therapeutics and currently in Phase I for Diabetic Neuropathic Pain. According to GlobalData,...